|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
5.000 -0.750 (-13.043%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 16,284,282 | 1.268% | 31,450,109 | 30,936,904 | 27,866,870 | 24,942,204 |
| Cost of Sales | (4,629,735) | -4.399% | (9,273,423) | (8,680,490) | (6,731,776) | (6,256,882) |
| Gross Profit | 11,654,547 | 3.710% | 22,176,686 | 22,256,414 | 21,135,094 | 18,685,322 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | 32,861 | 48,065 | 37,365 | 333,055 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (51,669) | 179.247% | (54,196) | (15,395) | 22,443 | 13,532 | |
| Profit / (Loss) before Taxation | 3,801,130 | 3.248% | 7,389,372 | 7,582,261 | 6,847,096 | 6,391,023 | |
| Taxation | (749,664) | 20.232% | (1,316,679) | (1,350,211) | (1,158,972) | (1,162,013) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (31,092) | -65.853% | (199,368) | (140,660) | (82,939) | (69,355) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,020,374 | 1.799% | 5,873,325 | 6,091,390 | 5,605,185 | 5,159,655 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (102,807) | -9.884% | (233,985) | (217,637) | (175,576) | (90,588) |
| Depreciation & Amortisation | 631,531 | 18.731% | 1,117,490 | 1,047,939 | 865,471 | 808,807 |
| Directors' Emoluments | -- | -- | 84,048 | 73,648 | 54,944 | 49,952 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 25.510 | 2.244% | 49.470 | 51.110 | 46.890 | 43.160 |
| DPS (cts) | 14.648 | -- | 25.399 | 18.386 | 14.959 | 10.678 |
| Dividend Payout Ratio (%) | 57.423% | -- | 51.342% | 35.973% | 31.902% | 24.741% |
| Cash flow per share ($) | -- | -- | 0.352 | 0.640 | 0.388 | 0.564 |
| NBV per share ($) | 2.930 | -- | 2.789 | 2.531 | 2.175 | 1.865 |
| Remarks: | Real time quote last updated: 01/11/2024 09:22 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,020,374 |
| %Change | 1.799% |
| EPS / (LPS) | RMB 0.255 |
| NBV Per Share (¥) | RMB 2.930 |